Latest net income for AKER: $-20M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2020
Trailing 12 months ending Dec 2020
Loading...
Loading...
As of the most recent data (December 2020), AKER shows a net income of $-20M. That compares with $-11M in the prior-year period — down 84.5% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AKER's net income is now $-20M (was $-11M) — a 84.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akers Biosciences is outperforming or lagging.
The Healthcare sector average net income is about $16B. Akers Biosciences is at $-20M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how AKER stacks up against individual peers as well.
Tracking AKER's net income over time shows whether Akers Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-20M That compares with $-11M in the prior-year period — down 84.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has Akers Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-20M) with ownership activity and broader fundamentals.